Psivant Therapeutics
Matthew Daniels is a highly experienced professional in the field of medicinal chemistry, currently serving as the Director at Psivant Therapeutics since October 2024. Prior to this role, Matthew held various positions at Accent Therapeutics, Inc., including Associate Director and Principal Scientist, and contributed significantly to Goldfinch Bio as a Senior Scientist and Scientist in Chemistry. Earlier experience includes roles at Novartis Institutes for BioMedical Research and Merck Research Labs, where Matthew designed and synthesized compounds, coordinated outsourcing for medicinal chemistry programs, and led project-based research efforts. Matthew's academic background includes a Bachelor’s and Master’s degree in Chemistry from Northeastern University, obtained between 2003 and 2007.
This person is not in any teams
Psivant Therapeutics
Psivant Therapeutics is advancing a paradigm shift in biotechnology by pioneering a physics-driven approach to drug design that is tightly coupled to chemistry and biology research and development. Our QUAISAR platform is purpose-built to develop novel small molecule therapeutics to address biologically and genetically validated, but previously intractable, protein targets.